☆ 4.7 Article

Dysregulation of iron homeostasis by TfR-1 renders EZH2 wild type diffuse large B-cell lymphoma resistance to EZH2 inhibition

ACTA PHARMACOLOGICA SINICA (2023)

Related references

Note: Only part of the references are listed.

Review Medicine, Research & Experimental

Hepcidin and Iron in Health and Disease

Elizabeta Nemeth et al.

Summary: Hepcidin, secreted by hepatocytes, controls the activity of ferroportin to regulate plasma iron concentrations and total body iron content. Iron loading and inflammation increase hepcidin levels, while erythropoietic stimulation and pregnancy suppress its levels. Hepcidin deficiency leads to iron overload, while hepcidin excess causes iron-restrictive anemias. Developing hepcidin diagnostics and therapeutics will improve the treatment of iron disorders.

ANNUAL REVIEW OF MEDICINE (2023)

Add to Collection

Article Oncology

Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma

Julie Devin et al.

Summary: Diffuse large B-cell lymphoma (DLBCL) is a common hematological malignancy, and alterations in iron metabolism may be targeted for therapy. Iron score (IS), a gene expression-based risk score, can identify high-risk DLBCL patients who may benefit from targeting iron homeostasis. Ironomycin, a potential treatment for DLBCL, inhibits cell proliferation and induces cell death.

CANCER RESEARCH (2022)

Add to Collection

Article Cell Biology

Ferroptosis Markers Predict the Survival, Immune Infiltration, and Ibrutinib Resistance of Diffuse Large B cell Lymphoma

Junmei Weng et al.

Summary: This study reveals the significance of ferroptosis in the prognosis, immune infiltration, and drug resistance of DLBCL patients. By constructing a ferroptosis-related risk score model, the overall survival and ibrutinib resistance of DLBCL patients can be predicted, which is associated with immunosuppressive status within the tumor microenvironment.

INFLAMMATION (2022)

Add to Collection

Article Oncology

Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study

Yue Lu et al.

Summary: A study on 32 PNH patients undergoing HID or MUD-HSCT showed no significant differences in 3-year OS and FFS between the two groups, but treatment-related mortality had a negative impact on outcomes. HID and MUD-HSCT are feasible and effective options for PNH patients with certain complications.

LEUKEMIA & LYMPHOMA (2022)

Add to Collection

Article Chemistry, Medicinal

Chlorogenic acid depresses cellular bioenergetics to suppress pancreatic carcinoma through modulating c-Myc-TFR1 axis

Hongbao Yang et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a severe malignant tumor in human, and chlorogenic Acid (CA) has been found to suppress PDAC cell growth by targeting the c-Myc-TFR1 axis, indicating its potential as a promising compound for PDAC treatment.

PHYTOTHERAPY RESEARCH (2021)

Add to Collection

Article Multidisciplinary Sciences

DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer

Chao Mao et al.

Summary: The study reveals the mechanism of ferroptosis induced by inhibiting GPX4 in cancer cells, as well as the potential pathways to enhance or inhibit ferroptosis by intervening in relevant metabolic pathways. Therapeutic strategies targeting different levels of GPX4 expression could be a promising new approach for cancer treatment.

NATURE (2021)

Add to Collection

Article Cell Biology

MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma

Yuxiong Lu et al.

Summary: MYCN amplification in pediatric neuroblastoma cells increases sensitivity to GPX4-targeting ferroptosis inducers by upregulating TFRC expression, leading to enhanced iron metabolism and lipid peroxidation, suggesting potential therapeutic strategies for treating MYCN-amplified NB.

CELL DEATH & DISEASE (2021)

Add to Collection

Article Multidisciplinary Sciences

Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes

Christina M. Bebber et al.

Summary: The loss of TP53 and RB1 in treatment-naive small cell lung cancer (SCLC) indicates a need to inactivate cell death pathways prior to therapy. This study identifies non-neuroendocrine (NE) SCLC as vulnerable to ferroptosis and neuroendocrine (NE) SCLC as susceptible to TRX pathway inhibition, with combining these treatments showing promise in overcoming subtype plasticity in SCLC.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

iPLA2β-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4

Delin Chen et al.

Summary: The study identifies iPLA2 beta as a critical regulator for p53-driven ferroptosis independent of GPX4. Loss of iPLA2 beta does not have obvious effect on normal cells, but it plays an essential role in regulating ferroptosis upon ROS-induced stress. iPLA2 beta is a promising therapeutic target for activating ferroptosis-mediated tumor suppression without serious toxicity concerns.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Medicine, Research & Experimental

Targeting iron metabolism in cancer therapy

Michael Morales et al.

Summary: Iron is crucial for cellular functions and human health, but excess iron can lead to oxidative DNA damage and cancer. Cancer cells are more dependent on iron than normal cells, making targeting iron metabolism in cancer cells an emerging and powerful therapeutic strategy.

THERANOSTICS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Ubiquitin-specific protease 7 promotes ferroptosis via activation of the p53/TfR1 pathway in the rat hearts after ischemia/reperfusion

Li-Jing Tang et al.

Summary: Iron overload induces ferroptosis in the heart post ischemia/reperfusion (I/R), with the USP7/p53/TfR1 pathway identified as promoting the ferroptosis. Inhibition of USP7 reduces ferroptosis and myocardial I/R injury by activating the p53/TfR1 pathway.

FREE RADICAL BIOLOGY AND MEDICINE (2021)

Add to Collection

Article Oncology

Gene Silencing of Transferrin-1 Receptor as a Potential Therapeutic Target for Human Follicular and Anaplastic Thyroid Cancer

Agata Campisi et al.

MOLECULAR THERAPY-ONCOLYTICS (2020)

Add to Collection

Review Oncology

EZH2: a novel target for cancer treatment

Ran Duan et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Review Oncology

Iron and Cancer: 2020 Vision

Suzy Torti et al.

CANCER RESEARCH (2020)

Add to Collection

Review Oncology

EZH2-Targeted Therapies in Cancer: Hype or a Reality

Marie-Lisa Eich et al.

CANCER RESEARCH (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy

Yuechen Zhao et al.

ONCOTARGETS AND THERAPY (2020)

Add to Collection

Article Oncology

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

Franck Morschhauser et al.

LANCET ONCOLOGY (2020)

Add to Collection

Review Oncology

Emerging epigenetic-modulating therapies in lymphoma

David Sermer et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Add to Collection

Review Oncology

BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer

Sofia Genta et al.

CURRENT ONCOLOGY REPORTS (2019)

Add to Collection

Review Oncology

Targeting Ferroptosis to Iron Out Cancer

Behrouz Hassannia et al.

CANCER CELL (2019)

Add to Collection

Article Multidisciplinary Sciences

Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling

Jiao Wu et al.

NATURE (2019)

Add to Collection

Article Multidisciplinary Sciences

The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis

Kirill Bersuker et al.

NATURE (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Iron Metabolism in Cancer

Yafang Wang et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Review Chemistry, Multidisciplinary

Emerging Strategies of Cancer Therapy Based on Ferroptosis

Zheyu Shen et al.

ADVANCED MATERIALS (2018)

Add to Collection

Article Oncology

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoine Italiano et al.

LANCET ONCOLOGY (2018)

Add to Collection

Review Pharmacology & Pharmacy

The Role of Ferroptosis in Cancer Development and Treatment Response

Bin Lu et al.

FRONTIERS IN PHARMACOLOGY (2018)

Add to Collection

Article Endocrinology & Metabolism

Prognostic Value of Transferrin Receptor-1 (CD71) Expression in Acute Lymphoblastic Leukemia

Adel A. Hagag et al.

ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors

Xun Huang et al.

CELL (2018)

Add to Collection

Review Oncology

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies

Rosemarie Tremblay-LeMay et al.

BIOMARKER RESEARCH (2018)

Add to Collection

Article Multidisciplinary Sciences

Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition

Matthew J. Hangauer et al.

NATURE (2017)

Add to Collection

Article Multidisciplinary Sciences

G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin

Ya-fang Wang et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Iron metabolism and drug resistance in cancer

Hasan Huseyin Kazan et al.

BIOMETALS (2017)

Add to Collection

Article Oncology

Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor

Daisuke Honma et al.

CANCER SCIENCE (2017)

Add to Collection

Article Oncology

HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells

Shan Zhu et al.

CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils

Yanfang Liu et al.

CANCER CELL (2016)

Add to Collection

Review Cell Biology

Ferrootosis: Death by Lipid Peroxidation

Wan Seok Yang et al.

TRENDS IN CELL BIOLOGY (2016)

Add to Collection

Article Plant Sciences

Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells

Edna Ooko et al.

PHYTOMEDICINE (2015)

Add to Collection

Article Biochemistry & Molecular Biology

Regulation of Ferroptotic Cancer Cell Death by GPX4

Wan Seok Yang et al.

CELL (2014)

Add to Collection

Review Oncology

EZH2: Not EZHY (Easy) to Deal

Gauri Deb et al.

MOLECULAR CANCER RESEARCH (2014)

Add to Collection

Article Oncology

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

Sarah K. Knutson et al.

MOLECULAR CANCER THERAPEUTICS (2014)

Add to Collection

Article Biochemistry & Molecular Biology

TfR1 interacts with the IKK complex and is involved in IKK-NF-kappa B signalling

Niall S. Kenneth et al.

BIOCHEMICAL JOURNAL (2013)

Add to Collection

Review Biochemistry & Molecular Biology

Transcriptional regulation by Polycomb group proteins

Luciano Di Croce et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)

Add to Collection

Review Biochemistry & Molecular Biology

Hepcidin and iron homeostasis

Tomas Ganz et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2012)

Add to Collection

Article Biochemistry & Molecular Biology

Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death

Scott J. Dixon et al.

CELL (2012)

Add to Collection

Article Multidisciplinary Sciences

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Michael T. McCabe et al.

NATURE (2012)

Add to Collection

Article Immunology

Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia

Celine Callens et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2010)

Add to Collection

Article Genetics & Heredity

PrognoScan: a new database for meta-analysis of the prognostic value of genes

Hideaki Mizuno et al.

BMC MEDICAL GENOMICS (2009)

Add to Collection

Article Biochemistry & Molecular Biology

Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis

KA O'Donnell et al.

MOLECULAR AND CELLULAR BIOLOGY (2006)

Add to Collection

Article Cell Biology

Lipooligosaccharide-independent alteration of cellular homeostasis in Neisseria meningitidis-infected epithelial cells

RA Bonnah et al.

CELLULAR MICROBIOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.